Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Purchased by United Bank

United Bank raised its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 6.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,426 shares of the medical equipment provider’s stock after acquiring an additional 589 shares during the quarter. United Bank’s holdings in Zimmer Biomet were worth $996,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Dunhill Financial LLC grew its holdings in shares of Zimmer Biomet by 1,090.0% in the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 218 shares in the last quarter. Stonebridge Financial Group LLC acquired a new stake in shares of Zimmer Biomet in the fourth quarter valued at $25,000. Brooklyn Investment Group purchased a new position in Zimmer Biomet in the third quarter valued at $35,000. Kentucky Trust Co acquired a new position in Zimmer Biomet during the 4th quarter worth $39,000. Finally, OFI Invest Asset Management purchased a new stake in Zimmer Biomet during the 4th quarter worth about $40,000. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, SVP Lori Winkler sold 1,443 shares of the stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total value of $150,649.20. Following the sale, the senior vice president now directly owns 8,768 shares in the company, valued at $915,379.20. This represents a 14.13 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.95% of the stock is currently owned by corporate insiders.

Zimmer Biomet Price Performance

Shares of NYSE ZBH opened at $112.21 on Friday. The company has a market cap of $22.34 billion, a PE ratio of 25.22, a P/E/G ratio of 1.95 and a beta of 1.04. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99. Zimmer Biomet Holdings, Inc. has a 1-year low of $97.69 and a 1-year high of $131.61. The stock has a fifty day moving average price of $107.18 and a 200 day moving average price of $107.02.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same quarter in the previous year, the company earned $2.20 earnings per share. Sell-side analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be paid a $0.24 dividend. The ex-dividend date is Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.86%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 21.57%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Raymond James decreased their price objective on Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating for the company in a research note on Friday, February 7th. Stifel Nicolaus boosted their price target on shares of Zimmer Biomet from $130.00 to $138.00 and gave the stock a “buy” rating in a report on Thursday, January 23rd. Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a report on Friday, February 7th. JMP Securities reiterated a “market outperform” rating and set a $140.00 target price on shares of Zimmer Biomet in a research note on Friday, February 7th. Finally, Barclays cut their price target on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating on the stock in a research note on Monday, February 10th. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $124.15.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.